TIGIT and non-small cell lung carcinoma: In addition, several ongoing clinical trials targeting TIGIT as the treatment of advanced solid cancers including non-small-cell lung cancer (such as NCT03119428, NCT02913313, NCT03563716, and NCT02794571), either as a single agent or in combination with other ICIs, are being performed (26).